Effects of Tucatinib on Cardiac Repolarization in Healthy Participants
Status:
Completed
Trial end date:
2019-03-11
Target enrollment:
Participant gender:
Summary
This study is looking at how the study drug, tucatinib, affects the heart. Tucatinib is being
studied as a possible treatment for breast cancer. This study will recruit healthy
volunteers. There are 3 parts in the study. Each volunteer will be in all 3 parts. One part
will be to take the study drug, the second part will be to take a placebo (pill with no
medicine), and the third part will be to take moxifloxacin. The volunteers will only know
what part of the study they are in when they take moxifloxacin. For the study drug and
placebo parts, volunteers will take 2 pills by mouth for 5 days. For the moxifloxacin part,
volunteers will take 1 pill by mouth for 1 day.
Phase:
Phase 1
Details
Lead Sponsor:
Seagen Inc. Seattle Genetics, Inc.
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination Tucatinib